Castle Biosciences Unveils Data on DecisionDx-Melanoma's Prognostic Capabilities for Early-Stage Melanoma
Castle Biosciences has announced new data regarding its DecisionDx-Melanoma test, which will be presented at the European Congress of Dermato-Oncology (EADO) and the American College of Mohs Surgery (ACMS) meetings. The data highlights the test's ability to provide personalized prognostic information for patients with early-stage cutaneous melanoma (CM), beyond what is offered by traditional American Joint Committee on Cancer (AJCC) staging. The study involved a large cohort of 1,817 patients and demonstrated that the test could significantly improve five-year recurrence risk predictions. It identified biologically high-risk patients within early-stage disease, whose recurrence rates were comparable to those with higher-stage melanoma. This suggests that the DecisionDx-Melanoma test can support more precise, risk-aligned management decisions, potentially leading to better patient outcomes. 
